Low to moderate levels of resistance to sICAM-1 inhibition emerge readily during in vitro passage of human rhinovirus 39 in the presence of sICAM-1 and appear phenotypically stable.
Answers are grounded in this paper and cite their sources.
Resistance to sICAM-1 may emerge readily in rhinovirus; leaves open durability of ICAM-1-based antivirals in clinical use.
Variants of human rhinovirus serotype 39 (HRV-39) relatively resistant to inhibition by soluble intercellular adhesion molecule-1 (sICAM-1) were selected by serial passages in HeLa or WI-38 cells in the presence of sICAM-1. Moderate resistance (four- to fivefold increases in 50% effective inhibitory concentrations [EC50s]) was observed after the second passage in HeLa cells and remained constant during six further passages in the presence of 10 micrograms of sICAM-1 per ml. A 7- to 17-fold increase in EC50s was observed in WI-38 cells during passage with 10 micrograms/ml, and reversion to a nonresistant phenotype was not observed after four passages in the absence of sICAM-1. Resistance of a higher degree was obtained by passing HRV-39 in the presence of 100 micrograms of sICAM-1 per ml in HeLa cells (30-fold EC50 increase). The sICAM-1-resistant phenotype was estimated to constitute 1 in 10(4) to 1 in 10(5) PFU of a nonexposed HRV-39 population. Low to moderate levels of resistance to sICAM-1 inhibition emerge readily during in vitro passage in the presence of sICAM-1 and appear to be phenotypically stable.
No takes yet. Share an insight, caveat, or question.
Arruda et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: